Download video

JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC

30 views

VJOncology

3 weeks ago

JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC

JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC

The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B \& More
5:52
The OncoAlert Weekly RoundUp September 12-18, 2025: PRIME | NECTIN-4 | PREOPANC-2 | WU-KONG1B \& More
by OncoAlert 360
JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC
3:58
JNJ-6420, an anti-hK2 antibody–based targeted radiotherapy, in mCRPC
by VJOncology
Cancer Cell | YTHDF2 inhibition potentiates radiotherapy antitumor efficacy
4:29
Cancer Cell | YTHDF2 inhibition potentiates radiotherapy antitumor efficacy
by pan zhengnan
Clinical Trial: JNJ-64251330 for Adenomatous Polyposis (NCT05014360)
2:06
Clinical Trial: JNJ-64251330 for Adenomatous Polyposis (NCT05014360)
by Power Life Sciences
First-In-Human Study Evaluating Safety of JNJ-6420 for mCRPC
6:06
First-In-Human Study Evaluating Safety of JNJ-6420 for mCRPC
by GU Oncology Now
First-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R\/R myeloma
3:09
First-in-human Phase I study of JNJ-5322, a novel trispecific antibody, in R\/R myeloma
by VJHemOnc – Video Journal of Hematology \& HemOnc
JCS 2. Microbiome and organ transplantation
1:00:42
JCS 2. Microbiome and organ transplantation
by Advanced VnPathoinformatics
What Living Unmedicated With Bipolar Type 1 is Like? Medication...
7:13
What Living Unmedicated With Bipolar Type 1 is Like? Medication...
by Bipolar Person
First-in-human JNJ-79635322 trispecific antibody study in RRMM patients: Initial phase 1 results
9:08
First-in-human JNJ-79635322 trispecific antibody study in RRMM patients: Initial phase 1 results
by International Myeloma Foundation
REZILIENT1: zipalertinib in pre-treated EGFR exon 20 insertion-mutant NSCLC
2:07
REZILIENT1: zipalertinib in pre-treated EGFR exon 20 insertion-mutant NSCLC
by VJOncology
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
1:11
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Evaluating erythrocyte-antibody conjugates in solid tumors
2:53
Evaluating erythrocyte-antibody conjugates in solid tumors
by VJOncology
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
0:55
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
by VJOncology
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
by VJOncology
Phase Ib study of JNJ-4496 in R\/R LBCL: early safety \& efficacy data
1:32
Phase Ib study of JNJ-4496 in R\/R LBCL: early safety \& efficacy data
by VJHemOnc – Video Journal of Hematology \& HemOnc
Initial results of JNJ-79635322, a novel next-generation trispecific antibody, in R\/R myeloma
3:36
Initial results of JNJ-79635322, a novel next-generation trispecific antibody, in R\/R myeloma
by VJHemOnc – Video Journal of Hematology \& HemOnc
Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
3:34
Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
by Journal of Human Immunity
If COVID Came from a Lab… Why Are We Acting Like It’s Gone?
14:35
If COVID Came from a Lab… Why Are We Acting Like It’s Gone?
by Vejon Health
Precision medicine in cancer: A new era
23:24
Precision medicine in cancer: A new era
by J\&J Innovative Medicine EMEA\
Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies
2:19
Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies
by VJHemOnc – Video Journal of Hematology \& HemOnc